Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V2GH
|
|||
| Former ID |
DAP000902
|
|||
| Drug Name |
Nicergoline
|
|||
| Synonyms |
MNE; Nargoline; Nicergolin; Nicergolina; Nicergolinum; Nicotergoline; Nimergoline; Sermion; Nicergolin [German]; Nicergolina [DCIT]; Nimergoline base; FI 6714; RP 19651; Nicergolinum [INN-Latin]; Sermion (TN); Nicergoline (JP15/USAN/INN); Nicergoline [USAN:BAN:INN:JAN]; Ergoline-8beta-methanol, 10-methoxy-1,6-dimethyl-, 5-bromonicotinate (ester); Ergoline-8-beta-methanol, 10-methoxy-1,6-dimethyl-, 5-bromonicotinate (ester); Ergoline-8beta-methanol, 10-methoxy-1,6-dimethyl-, 5-bromonicotinate (ester) (8CI); Ergoline-8-beta-methanol, 10-methoxy-1,6-dimethyl-, 5-bromo-3-pyridinecarboxylate (ester); Ergoline-8-methanol, 10-methoxy-1,6-dimethyl-, (8beta)-, 5-bromo-3-pyridinecarboxylate (ester); (+)-10-Methoxy-1,6-dimethylergoline-8-beta-methanol 5-bromonicotinate; 1-Methyl-lumilysergol 8-(5-bromonicotinate) 10-methyl ether; 10-Methoxy-1,6-dimethyl-ergolin-8-beta-methanol-(5-bromnicotinat); 10-Methoxy-1,6-dimethyl-ergolin-8-beta-methanol-(5-bromnicotinat) [German]; 10-Methoxy-1,6-dimethylergoline-8-methanol 5-bromo-3-pyrindinecarboxylate (ester); 10-Methoxy-1,6-dimethylergoline-8beta-methanol 5-bromonicotinate; 10-Methoxy-1,6-dimethylergoline-8beta-methanol 5-bromonicotinate (ester); 5-Bromonicotinic acid 10-methoxy-1,6-dimethylergoline-8-methyl ester; 8-beta-((5-Bromonicotinoyloxy)methyl)-1,6-dimethyl-10-alpha-methoxyergoline
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Brain ischaemia [ICD-11: 8B1Z; ICD-10: I67.8] | Approved | [1], [2] | |
| Senile dementia [ICD-11: 6D8Z] | Approved | [1], [2] | ||
| Therapeutic Class |
Vasodilator Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H26BrN3O3
|
|||
| Canonical SMILES |
CN1CC(CC2(C1CC3=CN(C4=CC=CC2=C34)C)OC)COC(=O)C5=CC(=CN=C5)Br
|
|||
| InChI |
1S/C24H26BrN3O3/c1-27-13-17-8-21-24(30-3,19-5-4-6-20(27)22(17)19)9-15(12-28(21)2)14-31-23(29)16-7-18(25)11-26-10-16/h4-7,10-11,13,15,21H,8-9,12,14H2,1-3H3/t15-,21-,24+/m1/s1
|
|||
| InChIKey |
YSEXMKHXIOCEJA-FVFQAYNVSA-N
|
|||
| CAS Number |
CAS 27848-84-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7848353, 8149729, 8173409, 11335299, 11360538, 11364264, 11366826, 11369388, 11372885, 11373939, 11377550, 11461510, 11466175, 11467295, 11485224, 11485929, 11489230, 11491748, 11492255, 11495184, 14834936, 14883615, 24897843, 26612185, 26680905, 26751796, 34675771, 46508741, 47290994, 47440109, 47588847, 47736318, 48184852, 48184853, 48259072, 48334339, 49698370, 49965496, 50104491, 50658085, 57311619, 57654463, 81092828, 85788051, 89449645, 92124960, 92125220, 92307617, 92308839, 93619685
|
|||
| ChEBI ID |
CHEBI:31902
|
|||
| SuperDrug ATC ID |
C04AE02
|
|||
| SuperDrug CAS ID |
cas=027848846
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides uniformis ATCC 8492
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nicergoline can be metabolized by Bacteroides uniformis ATCC 8492 (log2FC = -1.698; p = 0.036). | |||
|
Studied Microbe: Parabacteroides distasonis ATCC 8503
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nicergoline can be metabolized by Parabacteroides distasonis ATCC 8503 (log2FC = -0.69; p = 0.018). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
|
Studied Microbe: Escherichia coli BW25113
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nicergoline can be metabolized by Escherichia coli BW25113 (log2FC = -0.477; p = 0.011). | |||
|
Studied Microbe: Salmonella typhimurium LT2
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nicergoline can be metabolized by Salmonella typhimurium LT2 (log2FC = -0.567; p = 0.042). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia hansenii DSM20583
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nicergoline can be metabolized by Blautia hansenii DSM20583 (log2FC = -0.433; p = 0.034). | |||
|
Studied Microbe: Clostridium difficile 120
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nicergoline can be metabolized by Clostridium difficile 120 (log2FC = -2.744; p = 0.007). | |||
|
Studied Microbe: Clostridium sp.
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nicergoline can be metabolized by Clostridium sp. (log2FC = -0.482; p = 0.041). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor Alpha-2 (ADRA2) | Target Info | Antagonist | [4], [5] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drug information of Nicergoline, 2008. eduDrugs. | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 3 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 4 | Effect of non-selective alpha-adrenergic receptor antagonist nicergoline on the activity of neurons in the ventral lateral thalamic nucleus. Fiziol Zh. 2005;51(4):29-35. | |||
| REF 5 | Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a double-blind, placebo-controlled, clinical and EEG/ERP mapping study. Psychopharmacology (Berl). 1995 Feb;117(4):385-95. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.